2016 -- H 7468 | |
======== | |
LC004363 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2016 | |
____________ | |
A N A C T | |
RELATING TO COMMERCIAL LAW-- GENERAL REGULATORY PROVISIONS -- | |
UNFAIR SALES PRACTICES | |
| |
Introduced By: Representatives Lombardi, Regunberg, Handy, Carson, and McEntee | |
Date Introduced: February 04, 2016 | |
Referred To: House Corporations | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Title 6 of the General Laws entitled "UNFAIR SALES PRACTICES" is |
2 | hereby amended by adding the following chapter: |
3 | CHAPTER 13.1 |
4 | PRICE GOUGING OF PRESCRIPTION DRUGS PROHIBITED |
5 | 6-13.1-1. Purpose. -- To prohibit prescription drug price-gouging or excessive pricing |
6 | during market shortages. |
7 | 6-13.1-2. Findings. -- The general assembly finds: |
8 | (1) Many pharmaceutical drugs are necessary to maintain the health and welfare of the |
9 | American people; |
10 | (2) Currently the nation is facing a chronic shortage of vital drugs necessary in surgery, to |
11 | treat cancer, and to fight other life-threatening illnesses; and |
12 | (3) In order to prevent any party within the chain of distribution of any vital drugs from |
13 | taking unfair advantage of consumers during market shortages, the public interest requires that |
14 | such conduct be prohibited and made subject to criminal penalties. |
15 | 6-13.1-3. Definitions as used in this chapter.-- (1) "Biologic" means a virus, therapeutic |
16 | serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or |
17 | analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic |
18 | arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of |
| |
1 | human beings; |
2 | (2) "Drug" means a drug intended for use by human beings, which: |
3 | (i) Because of its toxicity or other potential for harmful effect, or the method of its use, or |
4 | the collateral measures necessary to its use, is not safe for use except under the supervision of a |
5 | practitioner licensed by law to administer such drug; or |
6 | (ii) Is limited by an approved application under §505 of the Federal Food, Drug, and |
7 | Cosmetic Act (21 U.S.C. 355) to use under the professional supervision of a practitioner licensed |
8 | by law to administer such drug; |
9 | (3) "Market emergency" means any declaration of a state of emergency by the governor |
10 | or by declaration by the President; |
11 | (4) "Market shortage" means a situation in which the total supply of all clinically |
12 | interchangeable versions of an FDA-regulated drug is inadequate to meet the current or projected |
13 | demand at the user level; |
14 | (5) "Price gouging" means charging a consumer an unreasonably high price for any drug |
15 | during a declared market emergency. This section shall not prohibit the fluctuation in the price of |
16 | drugs that occurs during the normal course of business; |
17 | (6) "Unreasonably excessive drug pricing" means the amount charged represents a gross |
18 | disparity between the average prices at which the same or similar commodity was readily |
19 | available and sold or offered for sale within the local area in the usual course of business during |
20 | the thirty (30) days immediately before the declaration of the market emergency and the |
21 | additional charges are not substantially attributable to increased cost to retailers, imposed by their |
22 | suppliers, including replacement costs imposed by the vendors' source. Additionally, the average |
23 | price calculation during said thirty (30) day period shall not include discounted prices set and |
24 | offered as a result of bona fide manufacturer's or supplier's limited discounts or rebates; and |
25 | (7) "Vital drug" means any drug or biologic used to prevent or treat a serious or life- |
26 | threatening disease or medical condition, for which there is no other available source with |
27 | sufficient supply of that drug or biologic or alternative drug or biologic available. |
28 | 6-13.1-4. Unreasonably excessive drug pricing. -- (a) The governor may issue an |
29 | executive order or rely on an executive order of the President, declaring a market shortage or |
30 | market emergency for a period of six (6) months with regard to one or more vital drugs due to a |
31 | market shortage under this chapter. |
32 | (b) If the governor or the President issues an executive order under subsection (a) of this |
33 | section, it shall be unlawful for any person to sell vital drugs at a price that is unreasonably |
34 | excessive and indicates that the seller is taking unfair advantage of the circumstances related to a |
| LC004363 - Page 2 of 5 |
1 | market shortage to unreasonably increase prices during such period. |
2 | (c) Authority. -- The attorney general is authorized to enforce penalties under this |
3 | chapter. |
4 | 6-13.1-5. Unreasonably excessive drug pricing. -- (a) If the governor or President |
5 | issues an executive order as described in §6-13.1-4, it shall be unlawful for any person to sell |
6 | vital drugs at a price that is unreasonably excessive and indicates that the seller is taking unfair |
7 | advantage of the circumstances related to a market shortage to unreasonably increase prices |
8 | during such period. |
9 | (b) Authority.-- The attorney general is authorized to enforce penalties under this chapter. |
10 | 6-13.1-6. Penalties. -- (a) Whoever sells, or offers to sell, any vital drug during a |
11 | declared market shortage with the knowledge and intent to charge a price that is unreasonably |
12 | excessive under the circumstances shall be guilty of a felony and shall be imprisoned for up to |
13 | five (5) years and by a fine of up to ten thousand dollars ($10,000) or both. |
14 | (b) Multiple Offenses.-- In assessing the penalty provided by subsection (a) of this |
15 | section each day of a continuing violation shall be considered a separate violation. |
16 | (c) Whenever it shall appear to the attorney general that any person or entity is engaged |
17 | in practices constituting a violation of any provision of this chapter and until such complaint is |
18 | dismissed by the attorney general or set aside by a court upon review, the attorney general may in |
19 | their discretion bring an action in the superior court for the county in which the violation has |
20 | occurred, to enjoin such acts or practices, and upon a proper showing a permanent or temporary |
21 | injunction or restraining order shall be granted in the interest of the general public. |
22 | 6-13.1-7. Determination of unreasonably excessive. -- (a) The attorney general, in |
23 | determining whether an alleged violator's price was unreasonably excessive, shall consider |
24 | whether: |
25 | (1) The price reasonably reflected additional costs, not within the control of that person |
26 | or company, that were paid, incurred, or reasonably anticipated by that person or company; |
27 | (2) The price reasonably reflected additional risks taken by that person or company to |
28 | produce, distribute, obtain, or sell such product under the circumstances; |
29 | (3) There is a gross disparity between the challenged price and the price at which the |
30 | same or similar goods were readily available in the state and prior to the same declared market |
31 | shortage; |
32 | (4) The marginal benefit received by the wholesaler or distributor is significantly changed |
33 | in comparison with marginal earnings in the year before a market shortage was declared; |
34 | (5) The price charged was comparable to the price at which the goods were generally |
| LC004363 - Page 3 of 5 |
1 | available in the New England area if the wholesaler or distributor did not sell or offer to sell the |
2 | prescription drug in question prior to the time a market shortage was declared; and |
3 | (6) The price was substantially attributable to local, regional, national, or international |
4 | market conditions. |
5 | (b) Consultation. Not later than one year after the date of enactment of this chapter and |
6 | annually thereafter, the attorney general or designee, shall consult with representatives of the |
7 | National Association of Wholesalers, group purchasing organizations, pharmaceutical |
8 | distributors, hospitals, manufacturers, patients, and other interested community organizations to |
9 | reassess the criteria set forth in subsection (a) of this section in determining unreasonably |
10 | excessive and prepare and submit to the general assembly a report on the results of the |
11 | reassessment. |
12 | 6-13.1-8. Duration. -- (a) Any market shortage declared by the governor or President in |
13 | accordance with this chapter shall be in effect for a period of not to exceed six (6) months from |
14 | the date on which the governor or President issues the executive order. |
15 | (b) Termination.-- Any market shortage declared by the governor or President in |
16 | accordance with this chapter shall terminate if: |
17 | (1) There is enacted a law terminating the market shortage which shall be passed by the |
18 | general assembly after a national market shortage is declared; or |
19 | (2) The governor or President issues a proclamation terminating the market shortage; |
20 | whichever comes first. |
21 | (c) Declaration Renewal. The governor or President may renew the state of market |
22 | shortage declared under subsection (a) of this section, if the governor or President declares that |
23 | the severe shortage continues to affect the health and well-being of citizens beyond the initial six |
24 | (6) month period. |
25 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC004363 | |
======== | |
| LC004363 - Page 4 of 5 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO COMMERCIAL LAW-- GENERAL REGULATORY PROVISIONS -- | |
UNFAIR SALES PRACTICES | |
*** | |
1 | This act would prohibit price gouging of prescribed drugs or pharmaceuticals in times of |
2 | market emergency or market shortages and would make violators guilty of a felony and would |
3 | make them subject to injunctive relief upon suit brought by the attorney general of the State of |
4 | Rhode Island. |
5 | This act would take effect upon passage. |
======== | |
LC004363 | |
======== | |
| LC004363 - Page 5 of 5 |